Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Is The Medibank (ASX:MPL) Share Price A Buy For The 7% Dividend Yield?

With a dividend yield of almost 7%, is the Medibank Private Limited (ASX:MPL) share price a buy?

Is the Medibank Private Limited (ASX: MPL) share price a buy for the 7% dividend yield, which includes franking credits?

Medibank is the largest listed private health insurer in Australia with its Medibank and AHM brands. It has been operating for over 40 years and has around 1.8 million policyholders & 3.7 million customers. The company is headquartered in Melbourne.

Is The Medibank Share Price A Buy For Income?

Medibank has one of the biggest dividend yields out of the blue chips, other than the banks. Its yield is 4.8% excluding franking credits and 6.9% including the effect of franking credits.

Income is in high demand at the moment because of the very low interest rates that banks are offering from bank savings accounts.

Medibank has increased its dividend each year since it listed in 2014, which is a fairly impressive streak. In Medibank’s latest half year result the private health insurer unveiled operating profit increased by 2.4% to $293 million and a dividend that was 3.6% higher than the year before.

One of the most attractive things to the idea of owning Medibank shares for the dividend is that the underlying demand for healthcare continues throughout the year and indeed over multi-year periods. Healthcare is one of the industries you can point to that has a good non-cyclical tailwind due to the ageing Australian population.

However, demand for private health insurance premiums isn’t looking so great at the moment due to the high and rising cost of premiums. Households are under a lot of budgetary pressures at the moment with little wage growth. Plus, Australia has one of the best public health systems in the world.

Things are looking even dicier at the moment because Medibank, NIB Holdings Limited (ASX: NHF) and others are being limited to very low average premium increases.

Medibank might be good for a slowly-growing dividend that is less affected by a recession, but I wouldn’t want to buy shares because of the prospect of limited total returns. I would rather buy one of the leading ASX shares that are outlined in the free report below.

[ls_content_block id=”14945″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content